Search

Your search keyword '"Zhao, W."' showing total 13 results
Start Over Author "Zhao, W." Journal annals of oncology
13 results on '"Zhao, W."'

6. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.

Author

Lim, S. H., Hong, J. Y., Lim, S. T., Hong, H., Arnoud, J., Zhao, W., Yoon, D. H., Tang, T., Cho, J., Park, S., Ko, Y. H., Kim, S. J., Suh, C., Lin, T., and Kim, W. S.

Subjects
*ANTHRACYCLINES, *CANCER chemotherapy, *KILLER cells, *T cells, *CANCER treatment, *THERAPEUTICS
Abstract

Background: Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy. Patients and methods: We retrospectively reviewed patients diagnosed with ENKTL at six centers in four countries (China, France, Singapore, and South Korea) from 1997 to 2015 and analyzed 179 patients who had relapsed or progressed after initial current standard therapy. Results: After a median follow-up of 58.6 months (range 27.9-89.2), the median second progression-free survival (PFS) was 4.1 months [95% confidence interval (CI) 3.04-5.16] and overall survival (OS) was 6.4 months (95% CI 4.36-8.51). Multivariate Coxregression analysis revealed that elevated lactate dehydrogenase, multiple extranodal sites (≥2), and presence of B symptoms were associated with inferior OS (P<0.05). OS and PFS were significantly different according to both prognostic index of natural killer lymphoma (PINK) and PINK-E (Epstein-Barr virus) models. Salvage chemotherapy with L-asparaginase (L-Asp)-based regimens showed a significantly better clinical benefit to response rate and PFS, although it did not lead to OS improvement. First use of L-Asp in the salvage setting and L-Asp rechallenge at least 6 months after initial treatment were the best candidates for salvage L-Asp containing chemotherapy. Conclusions: Most patients with relapsed or refractory ENKTL had poor prognosis with short survival. Further studies are warranted to determine the optimal treatment of patients with relapsed or refractory ENKTL. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

7. 22MO Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial.

Author

Xu, B., Ma, F., Wang, S., Tong, Z., Li, W., Wu, X., Wang, X., Sun, T., Pan, Y., Yao, H., Luo, T., Yang, J., Zeng, X., Zhao, W., Cong, X.J., Wang, N., Xu, C., and Chen, J.J.

Subjects
*TRIPLE-negative breast cancer, *CHINESE people, *SUBGROUP analysis (Experimental design)
Published
2022
Full Text
View/download PDF

8. 555P TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial.

Author

Wu, X., Liang, S., Chen, X., Hou, J., Wang, K., Wang, D., An, R., Zang, A., Li, X., Zhang, B., Qu, P., Duan, W., Yu, G., Yan, D., Wang, J., Yao, D., Wang, S., Zhao, W., and Lou, H.

Subjects
*ENDOMETRIAL cancer, *METASTASIS, *CLINICAL trials, *INJECTIONS, *THERAPEUTICS
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results